Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options

Drug Discovery Today

Volumn 16, Issue 1-2, 2011, Pages 8-21

  Wipfler, Peter ^a   Harrer, Andrea ^a   Pilz, Georg ^a   Oppermann, Katrin ^a   Trinka, Eugen ^a   Kraus, Jörg ^a  

^a Christian Doppler Klinik   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; ENCADIX; FINGOLIMOD; FUMARIC ACID; INTERFERON BETA SERINE; LAQUINIMOD; MINOCYCLINE; MITOXANTRONE; MOVECTRO; MYCOPHENOLIC ACID; NATALIZUMAB; OCRELIZUMAB; PLACEBO; RALENOVA; RITUXIMAB; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APPENDICITIS; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DEATH; DYSPNEA; EYE DISEASE; GONAD DYSFUNCTION; HERPES VIRUS INFECTION; HUMAN; INFECTION; LEUKEMIA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN CANCER;

ADMINISTRATION, ORAL; ANIMALS; DRUG APPROVAL; DRUG DESIGN; FORECASTING; HUMANS; MULTIPLE SCLEROSIS;

EID: 78651365410     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.10.011     Document Type: Review

References (114)

1. J.H. Noseworthy Multiple sclerosis N. Engl. J. Med. 343 2000 938 952
2. P. Sobocki Estimation of the cost of MS in Europe: extrapolations from a multinational cost study Mult. Scler. 13 2007 1054 1064 (Pubitemid 351541442)
3. F. Barkhof Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results Arch. Neurol. 64 2007 1292 1298 (Pubitemid 47403084)
4. K.P. Johnson Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
5. W.A. Sibley Physical trauma and multiple sclerosis Neurology 43 1993 1871 1874
6. C.H. Polman A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 354 2006 899 910 (Pubitemid 43313657)
7. T.A. Yousry Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N. Engl. J. Med. 354 2006 924 933 (Pubitemid 43313659)
8. G. Pilz Modern multiple sclerosis treatment - what is approved, what is on the horizon Drug Discov. Today 13 2008 1013 1025
9. P. Rieckmann Escalating immunotherapy of multiple sclerosis - new aspects and practical application J. Neurol. 251 2004 1329 1339
10. P. Rieckmann Nervenarzt 77 2006 1506 1518
11. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 1993 655 661 (Pubitemid 23121951)
12. L. Durelli Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) Lancet 359 2002 1453 1460 (Pubitemid 34457761)
13. G. Edan Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria J. Neurol. Neurosurg. Psychiatry 62 1997 112 118 (Pubitemid 27090928)
14. H.P. Hartung Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2002 2018 2025
15. PRISMS Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis Lancet 352 1998 1498 1504 (Pubitemid 28512925)
16. G. Comi Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
17. M. Trojano New natural history of interferon-beta-treated relapsing multiple sclerosis Ann. Neurol. 61 2007 300 306 (Pubitemid 46676729)
18. G. Comi Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study Lancet 357 2001 1576 1582 (Pubitemid 32488815)
19. R. Vosoughi, and M.S. Freedman Therapy of MS Clin. Neurol. Neurosurg. 112 2010 365 385
20. G.C. Ebers Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial J. Neurol. Neurosurg. Psychiatry 81 2010 907 912
21. E. Havrdova Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis Mult. Scler. 15 2009 965 976
22. D.B. Clifford Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol. 9 2010 438 446
23. H. Linda Progressive multifocal leukoencephalopathy after natalizumab monotherapy N. Engl. J. Med. 361 2009 1081 1087
24. W. Wenning Treatment of progressive multifocal leukoencephalopathy associated with natalizumab N. Engl. J. Med. 361 2009 1075 1080
25. K. Tan PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids Neurology 72 2009 1458 1464
26. P. Wipfler Long-term effects of natalizumab on cell surface bound adhesion molecules expression Mult. Scler. 15 2009 195
27. J.J. Marriott Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 74 2010 1463 1470
28. A.M. Pascual Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required Mult. Scler. 15 2009 1303 1310
29. G. Giovannoni A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N. Engl. J. Med. 362 2010 416 426
30. L. Kappos A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N. Engl. J. Med. 362 2010 387 401
31. A.D. Goodman Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial Lancet 373 2009 732 738
32. T.P. Leist, and P. Vermersch The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation Curr. Med. Res. Opin. 23 2007 2667 2676 (Pubitemid 350146405)
33. E. Beutler Cladribine (2-chlorodeoxyadenosine) Lancet 340 1992 952 956
34. G. Juliusson Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia J. Clin. Oncol. 14 1996 2160 2166 (Pubitemid 26230120)
35. E. Beutler The treatment of chronic progressive multiple sclerosis with cladribine Proc. Natl. Acad. Sci. U. S. A. 93 1996 1716 1720 (Pubitemid 26075191)
36. G.P. Rice Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group Neurology 54 2000 1145 1155
37. J.S. Romine A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis Proc. Assoc. Am. Physicians 111 1999 35 44 (Pubitemid 29047108)
38. T. Fujita Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite J. Antibiot. (Tokyo) 47 1994 208 215 (Pubitemid 24075577)
39. V. Brinkmann FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system Br. J. Pharmacol. 158 2009 1173 1182
40. G.M. Meno-Tetang Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses Drug Metab. Dispos. 34 2006 1480 1487
41. S.S. Chae Constitutive expression of the S1P1 receptor in adult tissues Prostaglandins Other Lipid Mediat. 73 2004 141 150
42. C.A. Foster Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis J. Pharmacol. Exp. Ther. 323 2007 469 475
43. J.A. Cohen Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N. Engl. J. Med. 362 2010 402 415
44. R.E. Jones Effects of 4-aminopyridine in patients with multiple sclerosis J. Neurol. Sci. 60 1983 353 362 (Pubitemid 13051185)
45. C.T. Bever, and S.I. Judge Sustained-release fampridine for multiple sclerosis Expert Opin. Investig. Drugs 18 2009 1013 1024
46. A. Solari Aminopyridines for symptomatic treatment in multiple sclerosis Cochrane Database Syst. Rev. 2002 2002 CD001330
47. A.R. Korenke Sustained-release fampridine for symptomatic treatment of multiple sclerosis Ann. Pharmacother. 42 2008 1458 1465
48. C.T. Bever Jr The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial Neurology 44 1994 1054 1059
49. H.A. van Diemen The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study Ann. Neurol. 32 1992 123 130
50. A.D. Goodman Interim analysis of open-label extension studies of dalfampridine extended release tablets in patients with multiple sclerosis Neurology 74 2010 A101
51. E. Le Page, and G. Edan Long-term experience with induction treatment regimens in multiple sclerosis J. Neurol. Sci. 277 Suppl. 1 2009 S46 S49
52. E. Le Page Comparison of two therapeutic strategies in aggressive relapsing-remitting MS: mitoxantrone as induction for 6 months followed by INF-β-1b versus INF-β-1b. A 3 year randomized trial Neurology 70 2008 A227
53. S.P. Cobbold Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms Prog. Clin. Biol. Res. 333 1990 139 151
54. A.J. Coles Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N. Engl. J. Med. 359 2008 1786 1801
55. A.A. Vandenbark, and R. Abulafia-Lapid Autologous T-cell vaccination for multiple sclerosis: a perspective on progress BioDrugs 22 2008 265 273 (Pubitemid 351969834)
56. B. Loftus Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies Clin. Immunol. 131 2009 202 215
57. M.S. Freedman The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group Mult. Scler. 16 2010 503 510
58. D. Farge Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases Haematologica 95 2010 284 292
59. D.E. Gladstone High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis Arch. Neurol. 63 2006 1388 1393
60. C. Krishnan Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis Arch. Neurol. 65 2008 1044 1051
61. I. Kassis Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis Arch. Neurol. 65 2008 753 761 (Pubitemid 351831453)
62. Y. Akiyama Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells J. Neurosci. 22 2002 6623 6630 (Pubitemid 35386418)
63. J.R. Munoz Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice Proc. Natl. Acad. Sci. U. S. A. 102 2005 18171 18176
64. F.J. Rivera Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells Stem Cells 24 2006 2209 2219
65. R.I. Spain Recent developments in multiple sclerosis therapeutics BMC Med. 7 2009 74
66. M.J. Craner Sodium channels contribute to microglia/macrophage activation and function in EAE and MS Glia 49 2005 220 229
67. R. Kapoor Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine J. Neurol. Sci. 274 2008 54 56
68. J.A. Black Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine Ann. Neurol. 62 2007 21 33
69. R. Kapoor Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial Lancet Neurol. 9 2010 681 688
70. M. Mantegazza Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders Lancet Neurol. 9 2010 413 424
71. J. Killestein Glutamate inhibition in MS: the neuroprotective properties of riluzole J. Neurol. Sci. 233 2005 113 115 (Pubitemid 40804825)
72. C. Pittenger Riluzole in the treatment of mood and anxiety disorders CNS Drugs 22 2008 761 786
73. L. Packer Neuroprotection by the metabolic antioxidant alpha-lipoic acid Free Radic. Biol. Med. 22 1997 359 378 (Pubitemid 26399344)
74. M. Morini Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis J. Neuroimmunol. 148 2004 146 153 (Pubitemid 38229567)
75. V. Yadav Lipoic acid in multiple sclerosis: a pilot study Mult. Scler. 11 2005 159 165 (Pubitemid 40403253)
76. G. Wolswijk Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord Brain 125 2002 338 349 (Pubitemid 34127436)
77. R. Linker Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination Crit. Rev. Immunol. 29 2009 43 68
78. V.W. Yong Prospects of repair in multiple sclerosis J. Neurol. Sci. 277 Suppl. 1 2009 S16 S18
79. S. Mi Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells Ann. Neurol. 65 2009 304 315
80. C.P. Kamm, and H.P. Mattle Swiss atorvastatin and interferon Beta-1b trial in multiple sclerosis (SWABIMS) - rationale, design and methodology Trials 10 2009 115
81. F. Paul Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis PLoS One 3 2008 e1928 (Pubitemid 351984117)
82. E. Krasulova High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience Mult. Scler. 16 2010 685 693
83. L. Rinaldi Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks Neurol. Sci. 30 Suppl. 2 2009 S171 S173
84. R.J. Schwartzman High-dose cyclophosphamide in the treatment of multiple sclerosis CNS. Neurosci. Ther. 15 2009 118 127
85. L. Kappos Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 372 2008 1463 1472
86. J. Preiningerova Oral laquinimod therapy in relapsing multiple sclerosis Expert Opin. Investig. Drugs 18 2009 985 989
87. A. Tselis Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis Curr. Opin. Investig. Drugs 11 2010 577 585
88. L.M. Metz Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial Mult. Scler. 15 2009 1183 1194
89. P. Vermersch Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis Eur. J. Neurol. 14 2007 85 89 (Pubitemid 46088042)
90. M. Togha Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a doubleblind randomized controlled trial Mult. Scler. 16 2010 848 854
91. M. Freedman Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results Neurology 74 2010 A293
92. M.S. Freedman Oral teriflunomide or placebo added to interferon beta for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results Mult. Scler. 15 2009 273
93. H. Wiendl Treatment of active secondary progressive multiple sclerosis with treosulfan J. Neurol. 254 2007 884 889 (Pubitemid 47222309)
94. A.J. Coles Alemtuzumab compared with subcutaneous high-dose IFN-beta-1a in treatment naive relapsing-remitting multiple sclerosis: primary efficacy outcomes of CAMMS223 at 3 years. CAMMS study group Neurology 70 Suppl. 1 2008 Abstract S22.006
95. O. Khan Alemtuzumab reduces disease progression in RRMS: long-term results of the CAMMS223 trial Neurology 74 2010 A371
96. J.W. Rose Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results Neurology 69 2007 785 789
97. D. Wynn Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta Lancet Neurol. 9 2010 381 390
98. M. Buttmann Treating multiple sclerosis with monoclonal antibodies: a 2010 update Expert Rev. Neurother. 10 2010 791 809
99. S.L. Hauser B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N. Engl. J. Med. 358 2008 676 688 (Pubitemid 351240747)
100. K. Hawker Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial Ann. Neurol. 66 2009 460 471
101. E. Wallström BAF312, a selective S1P1/S1P5 receptor modulator, effectively reduced absolute lamphocyte counts in human volunteers and demonstrates the relevance of S1P1 in mediating a transient heart rate reduction Neurology 74 2010 A420
102. C. Polman Double-blind, placebo-controlled randomized phase II serial MRI, safety and tolerability study of two doses of CDP323 in subjects with relapsing forms of multiple sclerosis over 24 weeks Neurology 74 2010 A293
103. H. Zahir Differential effects of a selective sphingosine 1-phosphate receptor 1 (S1P1) modulator (CS-0777) on circulating lymphocyte subsets in multiple sclerosis patients Neurology 74 2010 A366
104. R. Kapoor Outcomes of a phase II randomized controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis Mult. Scler. 15 2009 27
105. L.B. Krupp Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology 63 2004 1579 1585 (Pubitemid 39507572)
106. L.B. Krupp A multi-center randomized clinical trial of donepezil to treat memory impairment in multiple sclerosis Neurology 74 2010 A294
107. P.S. Sorensen Nordic trial of oral methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trial Lancet Neurol. 8 2009 519 529
108. M. Ravnborg Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial Lancet Neurol. 9 2010 672 680
109. R.A. Rudick Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N. Engl. J. Med. 354 2006 911 923 (Pubitemid 43313658)
110. A.D. Goodman GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study Neurology 72 2009 806 812
111. F. Patti A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN J. Neurol. Sci. 223 2004 69 71 (Pubitemid 38903265)
112. H.F. McFarland, and R. Martin Multiple sclerosis: a complicated picture of autoimmunity Nat. Immunol. 8 2007 913 919 (Pubitemid 47300005)
113. F.D. Lublin, and S.C. Reingold Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (U. S. A.) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Neurology 46 1996 907 911
114. B.G. Weinshenker The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability Brain 112 1989 133 146 (Pubitemid 19056478)